Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Circulating tumor cells (CTCs) with cancer stemness have been demonstrated to be a direct cause of tumor recurrence, and only few studies have reported the role of CTCs in liver transplantation (LT) for hepatocellular carcinoma (HCC). Methods: Epithelial cell adhesion molecule+ (EpCAM+), cluster of differentiation 90+ (CD90+) and EpCAM+/CD90+ CTCs were sorted via fluorescence-activated cell sorting, and transcripts level of EpCAM, K19 and CD90 in the peripheral blood were analyzed via real-time polymerase chain reaction preoperatively and on postoperative days 1 and 7 in 25 patients who underwent living donor liver transplantation (LDLT) for HCC. EpCAM protein was assessed in HCC tissue using immunohistochemical staining. The median follow-up duration was 40 months. Results: HCC after LDLT recurred in four out of 25 patients. Detection of EpCAM+ or CD90+ CTCs correlated well with their messenger RNA levels (p<0.05). EpCAM+ CTCs were readily detected in HCC tissue expressing EpCAM protein. The detection of EpCAM+ CTCs or EpCAM+/ CD90+ CTCs before surgery and on postoperative day 1 was significantly associated with HCC recurrence after LT (all p<0.05). Pretransplant serum PIVKA-II >100 mAU/mL and postoperative day 1 EpCAM+/CD90+ CTCs were independent risk factors for HCC recurrence (hazard ratio, 14.64; 95% confidence interval, 1.08 to 198.20; p=0.043 and hazard ratio, 26.88; 95% confidence interval, 1.86 to 387.51; p=0.016, respectively). Conclusions: EpCAM+/CD90+ CTCs can be used preoperatively and 1 day after LDLT as key biological markers in LT candidate selection and post-LDLT management.
Abstract
Background/Aims: Circulating tumor cells (CTCs) with cancer stemness have been demonstrated to be a direct cause of tumor recurrence, and only few studies have reported the role of CTCs in liver transplantation (LT) for hepatocellular carcinoma (HCC). Methods: Epithelial cell adhesion molecule+ (EpCAM+), cluster of differentiation 90+ (CD90+) and EpCAM+/CD90+ CTCs were sorted via fluorescence-activated cell sorting, and transcripts level of EpCAM, K19 and CD90 in the peripheral blood were analyzed via real-time polymerase chain reaction preoperatively and on postoperative days 1 and 7 in 25 patients who underwent living donor liver transplantation (LDLT) for HCC. EpCAM protein was assessed in HCC tissue using immunohistochemical staining. The median follow-up duration was 40 months. Results: HCC after LDLT recurred in four out of 25 patients. Detection of EpCAM+ or CD90+ CTCs correlated well with their messenger RNA levels (p<0.05). EpCAM+ CTCs were readily detected in HCC tissue expressing EpCAM protein. The detection of EpCAM+ CTCs or EpCAM+/ CD90+ CTCs before surgery and on postoperative day 1 was significantly associated with HCC recurrence after LT (all p<0.05). Pretransplant serum PIVKA-II >100 mAU/mL and postoperative day 1 EpCAM+/CD90+ CTCs were independent risk factors for HCC recurrence (hazard ratio, 14.64; 95% confidence interval, 1.08 to 198.20; p=0.043 and hazard ratio, 26.88; 95% confidence interval, 1.86 to 387.51; p=0.016, respectively). Conclusions: EpCAM+/CD90+ CTCs can be used preoperatively and 1 day after LDLT as key biological markers in LT candidate selection and post-LDLT management.
참고문헌 (33)
- Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis", N Engl J Med, 334, pp.693~699 (1996)
- Mazzaferro V, "Metroticket 2. 0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma", Gastroenterology, 154, pp.128~139 (2018)
- Tanaka F, "Circulating tumor cell as a diagnostic marker in primary lung cancer", Clin Cancer Res, 15, pp.6980~6986 (2009)
- Aceto N, "Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis", Cell, 158, pp.1110~1122 (2014)
- Tsai WS, "Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients", Sci Rep, 6, pp.24517~ (2016)
- Reya T, "Stem cells, cancer, and cancer stem cells", Nature, 414, pp.105~111 (2001)
- Ji J, "Clinical implications of cancer stem cell biology in hepatocellular carcinoma", Semin Oncol, 39, pp.461~472 (2012)
- Yang W, "Wnt", beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells, 2008, pp.68, 4287~4295
- Yang ZF, "Significance of CD90+cancer stem cells in human liver cancer", Cancer Cell, 13, pp.153~166 (2008)
- Terris B, "EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma", J Hepatol, 52, pp.280~281 (2010)
- Choi GH, "Increased expression of circulating cancer stem cell markers during the perioperative period predicts early recurrence after curative resection of hepatocellular carcinoma", Ann Surg Oncol, 3(Suppl 3), pp.S1444~S1452 (2015)
- Xue F, "Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation", Oncol Lett, 15, pp.5481~5488 (2018)
- Wang S, "Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation", J Investig Med, 66, pp.1~6 (2018)
- von Felden J, "Role of molecular biomarkers in liver transplantation for hepatocellular carcinoma", Liver Transpl, 26, pp.823~831 (2020)
- Kumar A, "Multiple roles of CD90 in cancer", Tumour Biol, 37, pp.11611~11622 (2016)
- Yamashita T, "Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma", Hepatology, 57, pp.1484~1497 (2013)
- Yamashita T, "Cancer stem cells in the development of liver cancer", J Clin Invest, 123, pp.1911~1918 (2013)
- Yamashita T, "EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem", progenitor cell features, 2009, pp.136, 1012~1024
- Tao Y, "Liver regeneration : analysis of the main relevant signaling molecules", Mediators Inflamm, 2017, pp.4256352~ (2017)
- Hu M, "Expansion and hepatic differentiation of adult blood-derived CD34+ progenitor cells and promotion of liver regeneration after acute injury", Stem Cells Transl Med, 5, pp.723~732 (2016)
- Tsui YM, "Cancer stemness in hepatocellular carcinoma : mechanisms and translational potential", Br J Cancer, 122, pp.1428~1440 (2020)
- Zhang L, "The stem cell niche of human livers : symmetry between development and regeneration", Hepatology, 48, pp.1598~1607 (2008)
- Lopresti A, "Sensitive and easy screening for circulating tumor cells by flow cytometry", JCI Insight, 5, pp.e128180~ (2019)
- Kuckuck FW, "High throughput flow cytometry", Cytometry, 44, pp.83~90 (2001)
- Goodale D, "Characterization of tumor cell dissemination patterns in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry", Cytometry A, 75, pp.344~355 (2009)
- Ho A, "Detection of infrequent cells in blood and bone marrow by flow cytometry" (2000), Marcel Dekker Inc
- Bocsi J, "Scanning fluorescent microscopy analysis is applicable for absolute and relative cell frequency determinations", Cytometry A, 61, pp.1~8 (2004)
- Grigg SE, "Systematic review with meta-analysis : sirolimus-or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma", Aliment Pharmacol Ther, 49, pp.1260~1273 (2019)
- Yin LC, "Twist expression in circulating hepatocellular carcinoma cells predicts metastasis and prognoses", Biomed Res Int, 2018, pp.3789613~ (2018)
- Fan ST, "Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells : a prospective study", Ann Surg, 254, pp.569~576 (2011)
- Sun YF, "Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection", Hepatology, 57, pp.1458~1468 (2013)
- Qi LN, "Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma", Cancer Res, 78, pp.4731~4744 (2018)
- Ou H, "Circulating tumor cell phenotype indicates poor survival and recurrence after surgery for hepatocellular carcinoma", Dig Dis Sci, 63, pp.2373~2380 (2018)